Cardiol Therapeutics Inc Class A (CRDL.TO) experienced a notable decline this week amidst a backdrop of significant recent developments.
This week, Cardiol Therapeutics Inc Class A stock closed at C$1.64, reflecting a 1.80% drop on the day and a 6.29% decrease over the week. Despite a strong year-to-date performance of 20.59%, the stock has faced downward pressure recently, primarily due to market dynamics rather than any specific company news.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$192.50M
52W high
$2.33
52W low
$1.23
1W change
-6.29%
Beta
0.51
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 265.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+265.9% Upside
Current Price
C$1.64
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
50.9%
Annualized
90-Day Vol
60.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.37
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.55 | C$1.30 – C$1.84 |
| 60 trading days | C$1.46 | C$1.14 – C$1.87 |
| 90 trading days | C$1.37 | C$1.01 – C$1.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should note the recent volatility in Cardiol Therapeutics' stock price, despite its promising developments in cardiac therapies. The stock's technical indicators suggest a stable long-term outlook, yet short-term fluctuations may present both opportunities and risks.
Cardiol Therapeutics Inc Class A has a market cap of C$192.5 million.
The stock has seen a volume of 111,361 shares traded, significantly above its 20-day average of 84,487 shares, indicating heightened investor interest.
Bull case
The positive outlook for Cardiol Therapeutics stems from its recent clinical trial successes and the publication of important study results that demonstrate the effectiveness of its cardiac therapies. Analysts have set a target price of C$6.00 for the stock, suggesting there is considerable upside potential.
Bear case
On the other hand, concerns about the stock's recent performance and the risks associated with biotech investments remain. These include regulatory challenges and competition in the market. Additionally, the company has not yet reached profitability, which may worry some investors.
Recent Price Action
Cardiol Therapeutics Inc Class A stock closed at C$1.64, marking a 1.80% decline for the day and a 6.29% decrease over the week. Despite these recent drops, the stock has appreciated by 20.59% since the beginning of the year, indicating a strong recovery from previous lows.
Technical Picture
The technical indicators for Cardiol Therapeutics show a 50-day moving average at C$1.61 and a 200-day moving average at C$1.55, both of which are above the current price, suggesting a potential support level. The stock has traded within a 52-week range of C$1.23 to C$2.33, with the current price at approximately 38% of this range. The stock's beta of 0.51 indicates lower volatility compared to the market, which may appeal to risk-averse investors. Recent trading volume of 111,361 shares is 1.32 times the 20-day average of 84,487 shares, reflecting increased interest.
Company News and Developments
While there have been no major announcements this week, Cardiol Therapeutics has recently achieved significant milestones, including the publication of Phase II study results in reputable journals, reinforcing the efficacy of its product CardiolRx™. This positive data may help bolster investor confidence and could influence future price movements.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
